Yuan Yuting, Kou Yunfeng, Yu Jian, Zhang Shenghe, Chen Songbai, Wang Ruoyu, Wang Zhe, Zhou Jun, Li Chuang
Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Center of Thermotherapy, Affiliated Zhongshan Hospital of Dalian University, China.
J Contemp Brachytherapy. 2024 Jun;16(3):202-210. doi: 10.5114/jcb.2024.141407. Epub 2024 Jun 30.
In the current study, the clinical efficacy of iodine-125 (I) radioactive particle implantation with deep hyperthermia in malignant tumor treatment was retrospectively analyzed.
Sixty patients with malignant tumors treated at Zhongshan Hospital affiliated with Dalian University, from January 2021 to January 2023, were included in this retrospective analysis. Computed tomography (CT)-guided I radioactive particles were implanted into lesions, followed by deep hyperthermia administered for 3 days after surgery. Lesion size was evaluated monthly using CT or magnetic resonance imaging (MRI), and objective response rate (ORR) and local control rate (DCR) were calculated. Mean pain numerical score and European Organization for Research and Treatment of Cancer quality of life core scale C30 (EORTC QLQ-C30 v. 3.0) were assessed pre-treatment and post-treatment, and post-operative adverse reactions were comparatively analyzed.
After 6 months, the combined treatment resulted in a 73.33% ORR and an 81.67% DCR among 60 patients experiencing pre-treatment pain, and 49 (81.67%) exhibited effective pain relief. EORTC QLQ-C30 v. 3.0 evaluation revealed improved quality of life post-treatment. Adverse reactions during combined treatment were mitigated with targeted supportive measures, and no adverse reactions of level 2 or higher were observed.
I radioactive particle implantation with deep hyperthermia is shown to be an effective combination therapy for malignant tumors, yielding significant clinical efficacy. Notably, it enhances patient quality of life, reduces tumor burden, mitigates adverse reactions, and alleviates pain. Given its minimal trauma and mild adverse reactions, this combination therapy warrants widespread clinical application.
在本研究中，回顾性分析碘-125（I）放射性粒子植入联合深部热疗在恶性肿瘤治疗中的临床疗效。
本回顾性分析纳入了2021年1月至2023年1月在大连大学附属中山医院接受治疗的60例恶性肿瘤患者。在计算机断层扫描（CT）引导下将I放射性粒子植入病灶，术后进行3天的深部热疗。每月使用CT或磁共振成像（MRI）评估病灶大小，并计算客观缓解率（ORR）和疾病控制率（DCR）。在治疗前和治疗后评估平均疼痛数字评分和欧洲癌症研究与治疗组织生活质量核心量表C30（EORTC QLQ-C30 v. 3.0），并对术后不良反应进行比较分析。
6个月后，在60例治疗前有疼痛的患者中，联合治疗的ORR为73.33%，DCR为81.67%，49例（81.67%）疼痛缓解有效。EORTC QLQ-C30 v. 3.0评估显示治疗后生活质量有所改善。联合治疗期间的不良反应通过针对性的支持措施得到缓解，未观察到2级或更高等级的不良反应。
碘-125放射性粒子植入联合深部热疗是一种有效的恶性肿瘤联合治疗方法，具有显著的临床疗效。值得注意的是，它提高了患者的生活质量，减轻了肿瘤负担，减轻了不良反应，并缓解了疼痛。鉴于其创伤小、不良反应轻，这种联合治疗方法值得在临床上广泛应用。
